Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

237.22 +22.78 (+10.62%)
Streaming Delayed Price Updated: 3:49 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
From ResMed Inc.
Via GlobeNewswire
Vaping Expected to Increase COPD Health and Economic Burden by 2050
From ResMed Inc.
Via GlobeNewswire
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Via Benzinga
Reasonable growth and debt and a high ROIC for RESMED INC (NYSE:RMD).
Why NYSE:RMD Stands Out as a Quality Stock. 
Via Chartmill
A Glimpse Into The Expert Outlook On ResMed Through 6 Analysts
Via Benzinga
How Is The Market Feeling About ResMed?
Via Benzinga
Why Quality-Oriented Investors Should Consider NYSE:RMD.
Exploring RESMED INC (NYSE:RMD)'s quality characteristics. 
Via Chartmill
NYSE:RMD may be ready to breakout.
There are signs that NYSE:RMD may be ready to breakout. 
Via Chartmill
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
$1000 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
Via Benzinga
RxSight Stock Sees Relative Strength Rating Rise To 91
On Monday, RxSight stock earned a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91. 
Via Investor's Business Daily
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
From ResMed Inc.
Via GlobeNewswire
Uncovering Dividend Opportunities with NYSE:RMD.
Is RESMED INC (NYSE:RMD) a Good Fit for Dividend Investing? 
Via Chartmill
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $9,500 Today
Via Benzinga
ResMed's Options Frenzy: What You Need to Know
Via Benzinga
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin improved significantly due to reduced costs and higher selling prices.... 
Via Benzinga
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $16,000 Today
Via Benzinga
What 6 Analyst Ratings Have To Say About ResMed
Via Benzinga
Looking Into ResMed's Recent Short Interest
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,600 Today
Via Benzinga
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Stock Market News From Amazon, Nike, McCormick, and More
We also talk with author Nicola Twilley about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves." 
Via The Motley Fool
Falling Knives: 3 Stocks Getting the Cold Shoulder From Analysts
Uncover key insights on stocks with negative analyst sentiment, including major moves by Alphabet, Nike and ResMed. 
Via InvestorPlace
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
From ResMed Inc.
Via GlobeNewswire
Is NYSE:RMD a Good Fit for Dividend Investing?
Uncovering Dividend Opportunities with RESMED INC (NYSE:RMD). 
Via Chartmill
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
We also talk about weight loss drugs and sleep apnea, and other stock market news. 
Via The Motley Fool
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
Sound Investments: 3 Stocks to Buy for a Good Night’s Rest
The safe stocks to buy for a good night’s rest aren’t the kind you’re thinking about. Nonetheless, they do make worthwhile investments. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.